Cited 0 times in
Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 변선정 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 천윤희 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2014-12-20T17:40:03Z | - |
dc.date.available | 2014-12-20T17:40:03Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/95033 | - |
dc.description.abstract | BACKGROUND: The prognosis and treatment outcomes of hepatocellular carcinoma (HCC) with inferior vena cava (IVC)/heart invasion have not been established. This study aimed to investigate the clinical characteristics and treatment outcomes of patients with HCC extending to IVC/heart and ascertained whether active treatment beyond best supportive care (BSC) can prolong overall survival. PATIENTS AND METHODS: We retrospectively reviewed 50 patients with HCC extending to IVC/heart who were admitted from November 1987 to November 2010. They were stratified into a control group with BSC alone (n=18) and a treated group with active treatment more than BSC (n=32). RESULTS: The mean age was 56.5 years and male gender predominated (n=39, 78.0%). Treatment modalities in the treated group included systemic chemotherapy using 5-fluorouracil with/without cisplatin (n=10, 31.3%), transarterial chemoembolization (n=8, 25.0%), intra-arterial chemotherapy (n=3, 9.4%), concurrent chemoradiation therapy (n=3, 9.4%), radiation (n=2, 6.2%), surgery (n=1, 3.1%), and of the combination above (n=5, 15.6%). Active treatment more than BSC was the only independent predictor of overall survival and the overall survival of the treated group was significantly better than that of the control group (median 4.0 vs. 2.0 months, p=0.003). CONCLUSION: The prognosis of HCC with IVC/heart invasion is poor. However, if patients are cautiously selected, active treatment beyond BSC might provide a survival benefit in patients with HCC extending to IVC/heart. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 4641~4646 | - |
dc.relation.isPartOf | ANTICANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Heart Neoplasms/secondary* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intra-Arterial | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardium/pathology* | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vena Cava, Inferior/pathology* | - |
dc.title | Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | YOON HEE CHUN | - |
dc.contributor.googleauthor | SANG HOON AHN | - |
dc.contributor.googleauthor | JUN YONG PARK | - |
dc.contributor.googleauthor | DO YOUNG KIM | - |
dc.contributor.googleauthor | KWANG-HYUB HAN | - |
dc.contributor.googleauthor | CHAE YOON CHON | - |
dc.contributor.googleauthor | SUN JEONG BYUN | - |
dc.contributor.googleauthor | SEUNG UP KIM | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A01850 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04029 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A03544 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J00188 | - |
dc.identifier.eissn | 1791-7530 | - |
dc.identifier.pmid | 22199343 | - |
dc.identifier.url | http://ar.iiarjournals.org/content/31/12/4641.long | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Byun, Sun Jeong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Chon, Chae Yoon | - |
dc.contributor.alternativeName | Chun, Yoon Hee | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Byun, Sun Jeong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Chun, Yoon Hee | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Chon, Chae Yoon | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 31 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 4641 | - |
dc.citation.endPage | 4646 | - |
dc.identifier.bibliographicCitation | ANTICANCER RESEARCH, Vol.31(12) : 4641-4646, 2011 | - |
dc.identifier.rimsid | 26996 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.